QLife
The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established
The Transaction was first announced by the Company through a press release on 5 June 2025. On 5 October 2025, the Company announced that the term and exclusivity of the non-binding Letter of Intent was extended and the Transaction would be conditional upon, inter alia, the signing of a share purchase agreement no later than 31 December 2025. Following the extension of the non-binding Letter of Intent, Nasdaq has informed the Company that it will not approve the contemplated Red Chip structure, as announced by the Company on 14 November 2025.
For more information about the intended terms of the Transaction, please refer to the press release that was published on 5 June 2025 "Qlife Holding AB: Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover".
This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 16-12-2025 08:30 CET
| Datum | 2025-12-16, kl 08:30 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!